Related references
Note: Only part of the references are listed.SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
Katrine M. Lauritsen et al.
DIABETES (2021)
Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure A Multimodality Study
Carlos G. Santos-Gallego et al.
JACC-CARDIOVASCULAR IMAGING (2021)
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
Milton Packer
DIABETES CARE (2020)
DESI-MSI and METASPACE indicates lipid abnormalities and altered mitochondrial membrane components in diabetic renal proximal tubules
Guanshi Zhang et al.
METABOLOMICS (2020)
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
Roni Nielsen et al.
CIRCULATION (2019)
Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus
Chantal Kopecky et al.
DIABETOLOGIA (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
Skander Mulder et al.
DIABETES OBESITY & METABOLISM (2019)
Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice
Masa-Ki Inoue et al.
DIABETOLOGY & METABOLIC SYNDROME (2019)
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats
Hiroto Oshima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
Soravis Osataphan et al.
JCI INSIGHT (2019)
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Chantal Mathieu et al.
DIABETES CARE (2018)
MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis
Jasmine Chong et al.
NUCLEIC ACIDS RESEARCH (2018)
The Warburg Effect in Diabetic Kidney Disease
Guanshi Zhang et al.
SEMINARS IN NEPHROLOGY (2018)
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
Debapriya Basu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Julio Rosenstock et al.
DIABETES CARE (2018)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A. DeFronzo et al.
NATURE REVIEWS NEPHROLOGY (2017)
Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients
Stein Hallan et al.
EBIOMEDICINE (2017)
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy
Michelle J. Pena et al.
DIABETES OBESITY & METABOLISM (2017)
Metabolomics Reveals a Key Role for Fumarate in Mediating the Effects of NADPH Oxidase 4 in Diabetic Kidney Disease
Young-Hyun You et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Evolving Concepts of Myocardial Energy Metabolism More Than Just Fats and Carbohydrates
Gary D. Lopaschuk et al.
CIRCULATION RESEARCH (2016)
The Role of Mitochondria in Diabetic Kidney Disease
Stein Hallan et al.
CURRENT DIABETES REPORTS (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
Francois Briand et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
SGLT2 Inhibitors and the Diabetic Kidney
Paola Fioretto et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Giuseppe Daniele et al.
DIABETES CARE (2016)
Mass Spectrometry Imaging Reveals Elevated Glomerular ATP/AMP in Diabetes/obesity and Identifies Sphingomyelin as a Possible Mediator
Satoshi Miyamoto et al.
EBIOMEDICINE (2016)
Mitochondrial Hormesis and Diabetic Complications
Kumar Sharma
DIABETES (2015)
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
Bruce A. Perkins et al.
PLOS ONE (2015)
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
Yuliya Lytvyn et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial
Bruce A. Perkins et al.
DIABETES CARE (2014)
Diabetes in the young - a global view and worldwide estimates of numbers of children with type 1 diabetes
Chris Patterson et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL (2014)
AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function
Laura L. Dugan et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
Kumar Sharma et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Sodium-glucose transport: role in diabetes mellitus and potential clinical implications
Volker Vallon et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2010)
New pharmacological treatments for improving renal outcomes in diabetes
Anne-Emilie Decleves et al.
NATURE REVIEWS NEPHROLOGY (2010)
Mechanisms of disease - The failing heart - An engine out of fuel
Stefan Neubauer
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data
N Chaturvedi
ANNALS OF INTERNAL MEDICINE (2001)
Share Paper
